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ABSTRACT
Background: The obese insulin-resistant state is characterized by
impairments in lipid metabolism. We previously showed that 3-d sup-
plementation of combined epigallocatechin-3-gallate and resveratrol
(EGCG+RES) increased energy expenditure and improved the
capacity to switch from fat toward carbohydrate oxidation with
a high-fat mixed meal (HFMM) test in men.
Objective: The present study aimed to investigate the longer-term
effect of EGCG+RES supplementation on metabolic profile, mito-
chondrial capacity, fat oxidation, lipolysis, and tissue-specific in-
sulin sensitivity.
Design: In this randomized double-blind study, 38 overweight
and obese subjects [18 men; aged 38 6 2 y; body mass index
(kg/m2): 29.7 6 0.5] received either EGCG+RES (282 and
80 mg/d, respectively) or placebo for 12 wk. Before and after the
intervention, oxidative capacity and gene expression were assessed
in skeletal muscle. Fasting and postprandial (HFMM) lipid metabo-
lism was assessed by using indirect calorimetry, blood sampling,
and microdialysis. Tissue-specific insulin sensitivity was assessed
by a hyperinsulinemic-euglycemic clamp with [6,6-2H2]-glucose
infusion.
Results: EGCG+RES supplementation did not affect the fasting
plasma metabolic profile. Although whole-body fat mass was not
affected, visceral adipose tissue mass tended to decrease after the
intervention compared with placebo (P-time 3 treatment = 0.09).
EGCG+RES supplementation significantly increased oxidative ca-
pacity in permeabilized muscle fibers (P-time 3 treatment ,
0.05, P-EGCG+RES , 0.05). Moreover, EGCG+RES reduced fast-
ing (P-time3 treatment = 0.03) and postprandial respiratory quotient
(P-time 3 treatment = 0.01) compared with placebo. Fasting and
postprandial fat oxidation was not significantly affected by EGCG
+RES (P-EGCG+RES = 0.46 and 0.38, respectively) but declined
after placebo (P-placebo = 0.05 and 0.03, respectively). Energy ex-
penditure was not altered (P-time 3 treatment = 0.96). Furthermore,
EGCG+RES supplementation attenuated the increase in plasma
triacylglycerol concentrations during the HFMM test that was ob-
served after placebo (P-time 3 treatment = 0.04, P-placebo =
0.01). Finally, EGCG+RES had no effect on insulin-stimulated glu-
cose disposal, suppression of endogenous glucose production, or
lipolysis.
Conclusion: Twelve weeks of EGCG+RES supplementation in-
creased mitochondrial capacity and stimulated fat oxidation compared
with placebo, but this did not translate into increased tissue-specific
insulin sensitivity in overweight and obese subjects. This trial was
registered at clinicaltrials.gov as NCT02381145. Am J Clin Nutr
2016;104:215–27.
Keywords: insulin sensitivity, mitochondrial capacity, obesity,
polyphenols, resveratrol
INTRODUCTION
The prevalence of obesity and related chronic diseases is
continuously increasing (1). Insulin resistance is a major risk
factor for the progression of obesity toward chronic metabolic
diseases, including cardiovascular disease and type 2 diabetes (2).
Reduced lipid storage capacity and impaired endocrine function
of adipose tissue (3) and decreased mitochondrial capacity and
accumulation of lipid intermediates in skeletal muscle (2, 4, 5)
are closely associated with insulin resistance.
Current treatment strategies to control the progression of
chronic diseases are mainly focused on lifestyle, pharmacologic,
or surgical interventions. However, these interventions showed
large interindividual variability in response (6), which underscores
the need for additional strategies to optimize the prevention of
obesity-associated metabolic disorders.
Polyphenols were identified as dietary ingredients with anti-
oxidant properties decades ago. More recently, they were also
implicated in the prevention of type 2 diabetes and cardiovascular
1 Supported by the ALPRO Foundation. Supplements were kindly pro-
vided by Pure Encapsulations, Inc.
2 SupplementalMethods, Supplemental Material, Supplemental Tables 1
and 2, and Supplemental Figures 1 and 2 are available from the “Online
Supporting Material” link in the online posting of the article and from the
same link in the online table of contents at http://ajcn.nutrition.org.
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diseases. As such, epigallocatechin-3-gallate (EGCG)6, which is
most abundant in green tea, and resveratrol, which is present in
grape skin, red wine, and peanuts, have been implicated in the
prevention of body weight gain and insulin resistance in rodents
fed obesogenic diets (7–9). In animal models of obesity, EGCG
was shown to reduce the absorption of intestinal lipids and to
increase lipid catabolism, possibly by inhibiting catechol-O-
methyltransferase (10) or by activating AMP kinase (AMPK)
(11). Resveratrol has been suggested to stimulate mitochondrial
biogenesis by activating sirtuin 1 (SIRT1) and peroxisome
proliferator–activated receptor g coactivator 1a (PGC1a) (7, 8).
Human studies have shown that supplementation with both
EGCG (or EGCG-rich products) and resveratrol improvedmarkers
of insulin sensitivity [HOMA-IR, EGCG (12), resveratrol (13)],
reduced plasma markers of oxidative stress (total antioxidative
status) and systemic inflammation [TNF-a, EGCG (12), resver-
atrol (13)], stimulated postprandial fat oxidation [EGCG (14)],
and reduced body weight [EGCG (15), resveratrol (16)]. How-
ever, conflicting data in humans have also been reported (17–19).
We recently postulated that a combination of polyphenols with
distinct mechanisms of action may have additional and/or syn-
ergistic effects, which may result in physiologically relevant
effects on fat oxidation. Indeed, we showed that supplementation
of a specific combination of EGCG and resveratrol (EGCG+RES)
for 3 d significantly increased resting and postprandial energy
expenditure (EE) and resulted in a more pronounced increase in
respiratory quotient (RQ) after a high-fat mixed meal (HFMM)
compared with placebo in men (20). Importantly, these effects
were not observed after single EGCG supplementation (21).
Here, we investigated the effects of longer-term combined EGCG
+RES supplementation on metabolic profile, skeletal muscle
oxidative capacity, fat oxidation, lipolysis, and peripheral, he-




Forty-two untrained (,3 h organized sports activities/wk),
weight-stable (,2 kg body weight change 3 mo before inclu-
sion) overweight and obese [BMI (in kg/m2) .25] white men
(n = 21) and women (n = 21) aged between 20 and 50 y with
normal glucose tolerance (fasting glucose ,6.1 mmol/L, 2-h
glucose ,7.8 mmol/L), normal blood pressure (diastolic:
60–90 mm Hg; systolic: 100–140 mm Hg) were included in this
study. Subjects were not allowed to donate blood or use any
medication or supplements that might interfere with study out-
comes for 3 mo before entering the study. Exclusion criteria were
pregnancy, menopause, lactation, and any reported history of
chronic inflammatory, cardiovascular, hepatic, pulmonary, renal,
or gastrointestinal disease. Intakes of caffeine (,600 mg/d),
green tea (,3 cups/d), alcohol (,20 g/d), and grapes and pea-
nuts (occasional consumption) had to be limited.
Study design and randomization
In this randomized, double-blind, placebo-controlled, parallel-
intervention trial, subjects received either a combination of
EGCG and RES supplements (EGCG+RES; 282 and 80 mg/d,
respectively) or a placebo (partly hydrolyzed microcrystalline
cellulose-filled capsules) for a period of 12 wk to assess effects of
EGCG+RES supplementation on tissue-specific insulin sensi-
tivity (primary outcome) and metabolic profile, skeletal muscle
oxidative capacity, fat oxidation, and lipolysis (secondary out-
comes). An independent researcher executed a block-wise ran-
domization procedure and packed the supplements according to
a computer-generated randomization plan (Microsoft Excel 2011
for Mac, Microsoft Corp.). The supplementation period started
the day after the last baseline measurement in week 0 and was
continued throughout measurements in week 12. Subjects were
instructed to maintain their habitual lifestyle pattern throughout
the study. In total, subjects were asked to visit the university 10
times for medical screening, 3 clinical investigation days (CIDs)
before the start of supplementation (within 7 d), 3 control visits
during the supplementation period, and 3 CIDs in the last week
of supplementation (within 7 d). CIDs comprised skeletal muscle
biopsies combinedwith dual-energyX-ray absorptiometry (CID1),
an HFMM test (CID2), and a hyperinsulinemic-euglycemic clamp
(CID3) and were separated by $1 d. Control visits for compliance,
side effects, and to provide new capsules were scheduled in weeks
2, 4, and 8 of intervention. During weeks 0 and 12, subjects were
asked to complete 3-d food records (2 weekdays, 1 weekend day)
and during week 4 a 1-d food record (1 weekday) to monitor and
control for changes in dietary habits. An experienced dietitian
checked the food records and discussed these with the subjects in
case of incomplete or missing information. Energy and nutrient
intakes were analyzed by using the Dutch Food Composition data
set (NEVO; National Institute for Public Health and the Envi-
ronment, Ministry of Health, Welfare, and Sport, Netherlands).
CIDs
Two days before the CIDs, subjects were asked to refrain from
intense physical activity and alcohol consumption. Meal intake
during the evening before each CID was standardized per subject
by providing the same meal. The first meal was provided ad
libitum (740 6 34 kcal, 48% 6 2% of energy from fat), and
subjects were asked to keep the portion size constant at all
subsequent CIDs. After an overnight fast, subjects came to the
university by car or public transport. Both before and after the
intervention, a 2-step hyperinsulinemic-euglycemic clamp and
an HFMM test were performed, and a skeletal muscle biopsy
sample was collected. All procedures were performed while
subjects were in a resting, half-supine position.
Dual-energy X-ray absorptiometry and skeletal muscle
biopsy (CID1)
First, body composition was measured by dual-energy X-ray
absorptiometry with the use of the 3-compartment model (Hologic
Corp.). Next, skeletal muscle (Vastus lateralis) biopsy samples
6Abbrevations used: AMPK, AMP activated kinase; CID, clinical investi-
gation day; EE, energy expenditure; EGCG, epigallocatechin-3-gallate;
EGCG+RES, epigallocatechin-3-gallate plus resveratrol; EGP, endogenous
glucose production; FFA, free fatty acid; HFMM, high-fat mixed meal;
NOGD, nonoxidative glucose disposal; OxPhos, oxidative phosphorylation;
PGC1a, peroxisome proliferator–activated receptor g coactivator 1a; post,
after intervention; pre, before intervention; Rd, rate of disappearance; RQ,
respiratory quotient; SIRT1, sirtuin 1.
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were taken under local anesthesia during fasting conditions
before and after the 12-wk intervention period. One portion
(w30 mg) was used for high-resolution respirometry (22),
which allows for the determination of oxidative capacity ex vivo
by quantifying the oxygen consumption with the use of the
Oxygraph-2k (Oroboros Instruments). The other portion was
directly frozen in isopentane and stored at 2808C until further
analyses. Protein quantification of mitochondrial oxidative
phosphorylation (OxPhos) complexes was performed by SDS-
PAGE followed by Western blot analysis with the use of nitro-
cellulose membranes (Trans-blot Turbo transfer system; Bio-Rad).
Blots were probed with Total OxPhos Antibody Cocktail
(Mitoscience/Abcam) and a secondary Infrared dye680/700
conjugated donkey anti-mouse antibody (Licor/Invitrogen).
Antigen-antibody complexes were visualized by using an
Odyssey Infrared Imaging System (Licor Biosciences).
A detailed description for skeletal muscle microarray analysis
and lipid composition is provided in the SupplementalMethods.
Briefly, for microarray analysis, 100 ng intact total RNA was
extracted from skeletal muscle biopsy samples by using the
Trizol method (Qiagen) and processed by applying the Gene-
Chip WT Plus Reagent Kit and Human Transcriptome Array 2.0
GeneChips (Affymetrix) according to the manufacturer’s in-
structions. Functional data analysis was based on a false-discovery
rate q-value ,0.2 on the filtered data set [IQR .0.2 (log2),
intensity .20, .5 arrays, .5 probes/gene].
For the determination of lipid composition, total lipids were
extracted after lyophilization of skeletalmuscle tissue. Diacylglycerol
and triacylglycerol were separated by thin-layer chromatography
and fatty acid profiles were determined on an analytic gas
chromatograph, as described previously (5).
Microdialysis (CID2)
Four microdialysis probes (CMA 60; CMA Microdialysis)
were inserted under local anesthesia, 2 in the medial portion of
the gastrocnemius muscle of both legs and 2 in the subcutaneous
adipose tissue 6–8 cm left and right from the umbilicus in male
subjects (n = 17; age: 40.1 6 2.0 y; BMI: 30.0 6 0.8; HOMA-
IR: 2.16 0.4), as described previously (23). After insertion, 90 min
were allowed for tissue recovery from the insertion trauma.
Throughout the HFMM test (CID2), in each tissue one probe
was perfused at 0.3 mL/min with Ringer solution to collect
microdialysate for analyses of glycerol, glucose, pyruvate, and
lactate concentrations by means of CMA enzymatic assay kits
on a CMA 600 microdialysis analyzer.
The contralateral probe was perfused at 5.0 mL/min with
Ringer solution, supplemented with 50 mmol ethanol/L, to assess
the ethanol outflow-to-inflow ratio as an indicator of local blood
flow. Ethanol concentrations were measured spectrophotometrically
at 340 nm by using a standard ethanol assay kit (Boehringer).
HFMM test (CID2)
After inserting a cannula into the antecubital vein, substrate
oxidation was measured for 30 min under fasting conditions
(t = 0) and for 4 h after the ingestion of a liquid HFMM (625 kcal,
61% of energy from fat, 33% of energy from carbohydrate, 6% of
energy from protein), which was consumed within 5 min at t = 0.
Blood samples were taken under fasting (t = 0 min) and post-
prandial (t = 30, 60, 90, 120, 150, 180, 210, and 240 min) con-
ditions. EE and substrate oxidation were measured by indirect
calorimetry by using the open-circuit ventilated hood system
(Omnical; Maastricht University) and were calculated according
to the formulas of Weir (24) and Frayn (25), respectively.
Hyperinsulinemic-euglycemic clamp (CID3)
A 2-step hyperinsulinemic-euglycemic clamp with [6,6-2H2]-
glucose infusion (tracer; Cambridge Isotope Laboratories) was
performed to assess the rate of disappearance (Rd), nonoxidative
glucose disposal (NOGD), and endogenous glucose production
(EGP) (22). First, a cannula was inserted into the antecubital vein.
A second cannula was inserted into a superficial dorsal hand vein
for the sampling of arterialized blood (by using a hot box with air
circulating at w508C). After the administration of a bolus in-
jection of 2.4 mg [6,6-2H2]-glucose/kg, a continuous [6,6-
2H2]-
glucose infusion was started at 0.04 mg/(kg3 min) and continued
throughout the measurement. After 2 h, insulin infusion was
started at 10 mU/(m2 3 min) for 2 h, followed by 40 mU/(m2
3min) insulin for the last 2 h to suppress lipolysis and EGP. By
a variable coinfusion of a 20% glucose solution, enriched to 1.92
mg tracer/mL, blood glucose concentrations were maintained at
5.0 mmol/L. During the last 30 min of each insulin-infusion step
[0, 10, and 40 mU/(m2 3 min)], blood samples were collected
and substrate oxidation was measured by using indirect calo-
rimetry [described in the section entitled “HFMM test (CID2)”] to
assess glucose kinetics. Kinetics of Rd and NOGD were calcu-
lated during 0 and 40 mU/(m2 3 min) insulin infusion, re-
spectively, as absolute increases between these steps [D mmol/(kg
3 min)], whereas calculations for insulin-mediated suppression
of EGP and free fatty acids (FFAs) were performed during 0 and
10 mU/(m2 3 min) insulin infusion, respectively, as relative
suppression during 10 compared with 0 mU/(m2 3 min) (%).
Biochemistry
Blood was collected into prechilled tubes and centrifuged
(1000 3 g; 10 min; 48C) and plasma was snap-frozen in liquid
nitrogen and stored at 2808C until analyses. To check for treat-
ment compliance, plasma epigallocatechin-3-gallate and resver-
atrol concentrations were determined by liquid chromatography–
mass spectrometry (for details, see Supplemental Methods).
In brief, for the measurement of free EGCG, 500 mL plasma
was combined with the same volume of an ascorbic acid/
EDTA stabilizing buffer. For analyses, an internal standard was
added, followed by a 23 liquid-liquid extraction. Total resver-
atrol and total dihydro-resveratrol were measured as the sum
of aglycone and conjugated forms (b-glucuronidase digestion
required) after the addition of labeled internal standard by
a liquid-liquid extraction. After centrifugation, an aliquot of the
organic phase was evaporated to dryness, re-dissolved in in-
jection solvent, and analyzed by using liquid chromatography–
mass spectrometry systems. The isotopic enrichment of plasma
glucose was determined by electron ionization gas chromatography–
mass spectrometry and expressed as the tracer-to-tracee ratio for
steady state calculations of Rd, NOGD, and EGP, as described
previously (22).
Plasma glucose, lactate, FFA, triacylglycerol, total cholesterol
and HDL-cholesterol concentrations were determined with an
automated spectrophotometer (ABX Pentra 400 autoanalyzer;
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HoribaABX) by using enzymatic colorimetric kits. LDL-cholesterol
concentrations were calculated by the Friedewald equation (26).
Plasma glycerol concentrations were measured with an enzy-
matic assay (Enzytec Glycerol; Roche Biopharm) automated on
aCobas Fara spectrophotometric autoanalyzer (RocheDiagnostics).
Circulating plasma concentrations of insulin, adiponectin, and leptin
were analyzed by using commercially available radioimmunoassay
kits (Human Insulin–specific Radioimmunoassay, Human Adi-
ponectin Radioimmunoassay, and Human Leptin Radioimmu-
noassay; Millipore Corporation). Plasma concentrations of
inflammatory markers (IL-6, IL-8, and TNF-a) were determined
by using a multiplex ELISA (Human ProInflammatory II 4-Plex
Ultra-Sensitive Kit; Meso Scale Diagnostics).
Supplements
The supplements were commercially available and were pro-
vided by Pure Encapsulations, Inc. All of the capsules were manu-
factured, tested, and checked in accordance to the standards of the
European Union’s Good Manufacturing Practices requirements.
EGCG capsules contained 94% epigallocatechin-3-gallate
(141mg/capsule, lot 3570112) and resveratrol capsules contained
20% trans-resveratrol (40 mg trans-resveratrol in Polygonum
cuspidatum extract/capsule, lot 1611011). The doses of the
supplements were based on previous study outcomes, in which
these doses altered markers of substrate and energy metabolism
[Timmers et al. (13): 150 mg resveratrol/d); Most et al. (20): 200 mg
resveratrol/d, 282 mg EGCG/d]. Higher concentrations appear
to have no (additional) benefit [Poulsen et al. (17): 1500 mg
resveratrol/d; Brown et al. (19): 800 mg EGCG/d]. Two lots of
placebo capsules (microcrystalline cellulose: lots 7150712 and
7160712) were used for blinding. Placebo capsules were en-
capsulated identically to the active supplements and filled with
microcrystalline cellulose and tan/brown and pink/red powder,
respectively, to blind both supplements. Capsules were packed
into white opaque boxes, labeled per subject without indication
of the content. One capsule of each supplement (EGCG and
resveratrol or both blinded placebo capsules) was ingested
during breakfast and dinner. This regimen was maintained until
the last measurement. On CIDs, subjects ingested the capsules
before arrival at the university (between 0700 and 0800 h). After
completion of the study, returned capsules were counted for
compliance and the stability of polyphenols was assessed by
measuring EGCG and resveratrol via HPLC in capsules stored
for 3 mo, according to the manufacturer’s recommendations.
The supplements were considered safe and well tolerated (20).
Study approval
All of the subjects gavewritten informed consent for participation
in this study, which was reviewed and approved by the local medical
ethics committee ofMaastricht UniversityMedical Center. This trial
was registered at clinicaltrials.gov (NCT02381145). All procedures
were conducted according to the Declaration of Helsinki.
Statistical analysis
The sample size (n = 42) was calculated to detect a physio-
logically relevant change in insulin sensitivity of 20%, with an
SD of 4%, a power of 80%, assuming a significance level of a =
0.05 (n = 34), and a drop-out rate of 20% (n = 8). All of the data
are expressed as means 6 SEMs. Data for the HFMM test are
expressed as AUCs to define the total measurement period
during this test (fasting and postprandial) and as incremental
AUCs to define specifically the postprandial response (diet-
induced effect compared with fasting), both calculated by the
trapezoid method. Variables were tested for normality by using
Shapiro-Wilk test and showed a normal distribution. Differences
in subjects’ characteristics at baseline were tested by Student’s
unpaired t test. Data were analyzed by using a 2-factor repeated-
measures ANOVA, with time [before intervention (pre) and after
intervention (post)] and treatment (placebo, EGCG+RES) as
factors. P , 0.05 was considered to be significant, and P , 0.10
was considered to show a trend. In case of a significant time 3
treatment interaction (P-time 3 treatment), post hoc analyses
with Bonferroni correction were applied to identify significant
within-group effects (P-EGCG+RES, P-placebo). In case of
clinically relevant baseline differences between treatment
groups (for fasting insulin, IL-6, mitochondrial capacity of
state 3 respiration, and protein expression of OxPhos com-
plexes III and V; for all, .20% baseline difference), the
baseline value was included as a covariate in univariate AN-
OVA, with the change over time as a dependent variable and
treatment as a between-subjects factor. In the ANOVA model,
no interactions between sex and the primary and secondary
outcomes were observed. Statistical analysis was performed
by using SPSS 19.0 (IBM Corporation) for Macintosh.
RESULTS
Subject characteristics and plasma biochemistry
Forty-two overweight and obese men and women volunteered
to participate in this study (August 2012–December 2013). In
total, 4 subjects (3 men, 1 women) did not complete the study
due to traveling abroad (n = 1), re-employment (n = 1), or
noncompliance with respect to supplementation or changing
lifestyle (n = 2). Characteristics of the 38 subjects (18 men, 20
women) who completed the study are summarized in Table 1.
There were no significant differences between the EGCG+RES
(n = 18; 8 men) and placebo (n = 20; 10 men) groups with re-
spect to baseline characteristics or self-reported moderate or
intense physical activity (EGCG+RES: 1.46 0.3 h/wk; placebo:
1.6 6 0.2 h/wk; P = 0.78).
Compliance was confirmed by counting returned supplements
(,3% of supplements were returned). Supplements were well
tolerated, and no adverse events were reported. Importantly,
plasma concentrations of EGCG, resveratrol, and dihydro-
resveratrol were significantly increased in all subjects who had
received EGCG+RES (Table 2), which indicated compliance to
the supplementation regimen. No significant changes in fasting
plasma concentrations of glucose, insulin, lactate, glycerol,
FFAs, or triacylglycerol were observed (Table 2, Figure 1A–F).
Likewise, fasting plasma concentrations of leptin, adiponectin,
and the inflammatory markers IL-6, IL-8, and TNF-a were not
significantly affected by the intervention (Table 2). Furthermore,
fasting plasma concentrations of total cholesterol, HDL cho-
lesterol, and LDL cholesterol were not significantly changed
after 12 wk of EGCG+RES supplementation compared with
placebo. However, the ratio of total cholesterol to HDL cho-
lesterol, a marker for myocardial infarction risk (27), tended to
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decrease after EGCG+RES supplementation but not after
placebo (P-time 3 treatment = 0.03, P-EGCG+RES = 0.09,
P-placebo = 0.13; Table 2). Adjustments for clinically relevant
differences in baseline values (fasting insulin and IL-6) did not
alter the outcome of the analysis (.20% baseline difference).
EGCG+RES did not alter food intake and body
composition
Food intake, assessed by using self-reported 3-d food records,
did not change after supplementation in either group (EGCG
+RES: 2092 6 200 kcal/d, 45% 6 1% of energy from carbo-
hydrate, 39% 6 1% of energy from fat, 15% 6 1% of energy
from protein; placebo: 1982 kcal/d, 45% 6 2% of energy from
carbohydrate, 38% 6 2% of energy from fat, 16% 6 1% of
energy from protein). Body weight, body fat percentage, and
body fat distribution (upper and lower body fat mass) were not
significantly altered by EGCG+RES supplementation (Table 3).
Interestingly, however, there was a tendency toward a differen-
tial effect on visceral adipose tissue mass, with a tendency
toward a decrease after EGCG+RES compared with placebo
(P-time 3 treatment = 0.09).
EGCG+RES increased skeletal muscle oxidative capacity
Next, we investigated whether skeletal muscle oxidative ca-
pacity increased after 12 wk of EGCG+RES supplementation,
because we previously showed that resveratrol supplementation
for 30 d improved mitochondrial capacity (13). Therefore, ex
vivo mitochondrial respiration with the use of different substrate
combinations was determined in isolated human permeabilized
skeletal muscle fibers (22).
Basal respiration [placebo (pre): 6.95 6 0.96; placebo (post):
3.93 6 1.03; EGCG+RES (pre): 3.67 6 1.17; and EGCG+RES
(post): 4.87 6 1.04 pmol O2 $ mg muscle
21 $ s21] increased by
w10-fold by the addition of ADP (state 3 respiration over basal
respiration, with malate and glutamate as substrates; data not
shown). This indicates that the permeabilized fibers are reactive
to ADP and the mitochondrial ADP transport is intact and
functioning. ADP-stimulated complex I–linked respiration with
the addition of malate + glutamate was not affected by EGCG
+RES supplementation (data not shown). In addition, respiration
with a fatty acid substrate, assessed by input of malate + octanoyl-






(n = 18) P (t test)
Age, y 38.7 6 2.2 36.1 6 2.2 0.43
BMI, kg/m2 29.5 6 0.7 29.9 6 0.6 0.67
Waist-hip ratio 0.87 6 0.02 0.87 6 0.02 0.78
Systolic blood pressure, mm Hg 114 6 2 117 6 2 0.27
Diastolic blood pressure, mm Hg 76 6 2 76 6 2 0.86
Fasting plasma glucose, mmol/L 5.10 6 0.08 5.19 6 0.09 0.44
2-h Glucose, mmol/L 5.38 6 0.21 5.34 6 0.24 0.92
HbA1c, % 5.15 6 0.06 5.12 6 0.06 0.76
Hemoglobin, mmol/L 8.9 6 0.1 8.6 6 0.2 0.22
Hematocrit, L/L 0.43 6 0.01 0.39 6 0.02 0.18
Creatinine, mmol/L 79.5 6 3.7 74.2 6 2.7 0.29
ALT, U/L 27.9 6 4.4 26.9 6 2.2 0.86
1Values are means 6 SEMs. Data were analyzed by using a Student’s
unpaired t test. P , 0.05 was considered significant for the difference between
placebo and EGCG+RES groups. ALT, alanine aminotransferase; EGCG
+RES, epigallocatechin-3-gallate plus resveratrol; HbA1c, glycated hemoglo-
bin; 2-h Glucose, plasma glucose concentration 2 h after oral glucose ingestion.
TABLE 2
Fasting plasma biochemistry before and after 12 wk of supplementation with EGCG+RES or placebo1
Placebo (n = 20) EGCG+RES (n = 18) P
Week 0 Week 12 Week 0 Week 12 Time Treatment Time 3 treatment
EGCG, nmol/L ,5.45 ,5.45 ,5.45 32.7 6 13.1*
Resveratrol, nmol/L ,43.8 ,43.8 ,43.8 1200.5 6 220*
Dihydro-resveratrol, nmol/L ,43.4 ,43.4 ,43.4 833.8 6 121.6*
Glucose, mmol/L 5.0 6 0.1 5.1 6 0.1 5.1 6 0.1 5.1 6 0.1 0.75 0.61 0.69
Insulin, mU/L 10.1 6 1.5 10.0 6 1.0 8.1 6 1.0 7.4 6 0.6 0.54 0.10 0.67
HOMA-IR 2.3 6 0.4 2.2 6 0.2 1.8 6 0.2 1.7 6 0.1 0.57 0.12 0.74
FFAs, mmol/L 553 6 33 533 6 43 523 6 24 555 6 35 0.89 0.92 0.37
Triacylglycerol, mmol/L 1.29 6 0.16 1.52 6 0.16 1.61 6 0.23 1.61 6 0.24 0.13 0.46 0.17
Cholesterol, mmol/L 5.9 6 0.3 5.8 6 0.3 6.0 6 0.2 5.8 6 0.2 0.13 0.81 0.49
HDL cholesterol, mmol/L 1.23 6 0.07 1.20 6 0.07 1.27 6 0.08 1.29 6 0.09 0.66 0.57 0.14
LDL cholesterol, mmol/L 4.40 6 0.27 4.30 6 0.27 4.45 6 0.22 4.20 6 0.16 0.06 0.94 0.39
Cholesterol:HDL cholesterol 5.09 6 0.34 5.27 6 0.43 5.16 6 0.42 4.94 6 0.42 0.94 0.82 0.03
Adiponectin, mg/mL 9.01 6 0.85 9.64 6 1.05 8.74 6 0.82 8.99 6 0.87 0.15 0.93 0.52
Leptin, ng/mL 23.4 6 4.2 22.7 6 4.1 19.8 6 2.4 18.2 6 2.4 0.28 0.41 0.65
IL-6, pg/mL 0.96 6 0.17 0.83 6 0.11 0.77 6 0.07 0.85 6 0.13 0.93 0.68 0.25
IL-8, pg/mL 9.25 6 0.61 9.82 6 0.86 9.80 6 0.93 9.19 6 0.70 0.98 0.97 0.26
TNF-a, pg/mL 2.84 6 0.21 3.15 6 0.42 2.69 6 0.18 2.63 6 0.15 0.34 0.35 0.20
1Values are means 6 SEMs. Data were analyzed by using 2-factor repeated-measures ANOVA, with time (pre, post) and treatment (placebo, EGCG
+RES) as factors. For EGCG, resveratrol, and dihydro-resveratrol, 2.5, 10, and 10 ng/mL, respectively, were detection limits. P , 0.05 was considered
significant. No baseline differences were observed (Student’s t test). *, In case of a significant time 3 treatment interaction, post hoc analyses with Bonferroni
correction were applied to identify significant within-group effects. Except for polyphenol concentrations, no significant within-group effects were found.
EGCG, free plasma epigallocatechin-3-gallate; EGCG+RES, epigallocatechin-3-gallate plus resveratrol; FFA, free fatty acid; post, after intervention; pre,
before intervention; Resveratrol, plasma total resveratrol.
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treatment = 0.19; Figure 2A). Interestingly, however, we found
that mitochondrial respiration on the electron input of both com-
plexes I and II (state 3, complex I and II), assessed by the addition
of succinate after malate + glutamate (MGS) or after malate +
octanoyl-carnitine + glutamate (MOGS), increased in the EGCG
+RES group compared with the placebo group after 12 wk
of supplementation [state 3 respiration (MGS): P-time 3 treat-
ment = 0.01, P-EGCG+RES = 0.01, P-placebo = 0.26; state
3 respiration (MOGS): P-time3 treatment = 0.05, P-EGCG+RES
, 0.01, P-placebo = 0.45; Figure 2B, C]. Despite randomization,
there was a difference in state 3 mitochondrial respiration at base-
line between groups (P-pre = 0.01), which was inversely correlated
to the change in this variable over time (r = 20.57, P , 0.01). For
this reason, baseline state 3 respiration was included as a covariate
in the analysis.
Furthermore, maximal mitochondrial respiration, as de-
termined by titration of the chemical uncoupler carbonyl cyanide
p-trifluoromethoxyphenylhydrazone, increased after EGCG
+RES supplementation compared with placebo (P-time 3
treatment = 0.01, P-EGCG+RES = 0.01, P-placebo = 0.31; Figure
2D). Mitochondrial proton leak, which was assessed by the addition
of the ATP synthase inhibitor oligomycin, was not significantly
FIGURE 1 Fasting and postprandial insulin and metabolite concentrations before and after intervention. Values are means 6 SEMs; n = 38. Plasma
insulin (A) and metabolite (B–F) concentrations are shown after an overnight fast (at 0 min) and after an HFMM (from 0 to 240 min). Fasting values (t = 0),
AUCs during the HFMM test (calculated from t = 0–240 min), and incremental AUCs were analyzed by using 2-factor repeated-measures ANOVA, with time
[P-time (pre, post)] and treatment [P-treatment (placebo, EGCG+RES)] as factors. P , 0.05 was considered significant. No time 3 treatment interactions
were observed on fasting concentrations and incremental AUCs. Reported P values refer to the respective AUCs. In case of a significant time 3 treatment
interaction (P-time 3 treatment), post hoc analyses with Bonferroni correction were applied to identify significant within-group effects (EGCG+RES, P;
placebo, P). EGCG+RES, epigallocatechin-3-gallate plus resveratrol; HFMM, high-fat mixed meal; PLA, placebo; post, after intervention; pre, before
intervention.
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affected by the intervention (state 4o, P-time 3 treatment = 0.10;
Figure 2E).
EGCG+RES increased oxidative metabolism pathways at
the transcriptional and translational levels
To identify pathways that may underlie the EGCG+RES-induced
improvement in mitochondrial capacity, we next determined
whether protein expression of OxPhos complexes in skeletal muscle
was altered by EGCG+RES. We found an EGCG+RES-induced
increase in complexes III (P-time 3 treatment = 0.03, P-EGCG
+RES = 0.04, P-placebo = 0.35) and V (P-time 3 treatment ,
0.01, P-EGCG+RES , 0.01, P-placebo = 0.29) compared with
placebo (Figure 2G, H). Despite randomization, there was a dif-
ference in complexes III and Vat baseline between groups (.20%
baseline difference). Adjustment for these baseline values did not
alter the outcome of the analysis. On the basis of these findings, we
performed microarray analysis on skeletal muscle biopsy samples
(Vastus lateralis) collected before and after 12 wk of EGCG+RES
or placebo treatment. Indeed, gene set enrichment analysis in-
dicated that the most upregulated pathways after EGCG+RES
supplementation were related to the citric acid cycle and re-
spiratory electron transport chain, whereas pathways related to
carbohydrate metabolism were upregulated in the placebo group
(Figure 3, Supplemental Table 1). Taken together, these data
indicate that the increased mitochondrial capacity after EGCG
+RES supplementation is accompanied by changes at the tran-
scriptional and translational levels.
EGCG+RES affects fat oxidation without changes in EE
Next, we investigated whether the improved skeletal muscle
oxidative capacity after 12 wk of EGCG+RES supplementation
translates into whole-body effects on fasting substrate oxidation.
Indeed, EGCG+RES supplementation significantly affected
fasting substrate oxidation, as reflected by no change in fasting
RQ after EGCG+RES and a significant increase in the placebo
group [EGCG+RES (pre): 0.803 6 0.009; EGCG+RES (post):
0.785 6 0.016; placebo (pre): 0.784 6 0.009; placebo (post):
0.821 6 0.015; P-time 3 treatment = 0.03, P-EGCG+RES =
0.31, P-placebo = 0.04] (Figure 4A), without effects on EE
(Figure 4B). More specifically, an increase in fasting carbohy-
drate oxidation was observed after placebo but not after EGCG
+RES (P-time 3 treatment = 0.05, P-EGCG+RES = 0.44,
P-placebo = 0.04) supplementation. Furthermore, EGCG+RES
did not change fasting fat oxidation, whereas there was a signifi-
cant decrease in the placebo group after 12 wk of supplementation
compared with week 0 (P-time 3 treatment = 0.06, P-EGCG
+RES = 0.46, P-placebo = 0.05; Figure 4C, D).
EGCG+RES affects triacylglycerol concentrations but did
not change postprandial responses of substrate oxidation
and local lipolysis
To examine EGCG+RES-induced effects on postprandial
substrate utilization and EE, we performed an HFMM test (625
kcal, 61% of energy from fat). More specifically, we determined
whole-body, adipose tissue, and skeletal muscle substrate me-
tabolism in the postprandial state by combining plasma blood
sampling, indirect calorimetry, and microdialysis.
The effects of 12 wk of EGCG+RES supplementation on
substrate oxidation in the absence of changes in EE in the fasting
state were maintained throughout the postprandial period (Figure
4E–H). More specifically, postprandial fat oxidation (AUC) was
reduced in the placebo group in week 12 compared with week
0 (P-placebo = 0.03), whereas no significant effect of EGCG
+RES was observed (P-EGCG+RES = 0.38; Figure 4H). In
addition, the intervention-induced changes in EGCG, resver-
atrol, and dihydro-resveratrol plasma concentrations did not
significantly correlate with EGCG+RES-induced effects on fat
oxidation (data not shown).
The postprandial responses after meal intake (incremental
AUC) of RQ, EE, carbohydrate, and fat oxidation as well as the
postprandial responses of plasma metabolites and insulin were
not significantly affected by the intervention (Figure 4I–L and
Figure 1A–F, respectively).
Importantly, however, plasma triacylglycerol concentrations
during the HFMM test were significantly increased in the placebo
group after 12 wk but not in the EGCG+RES group [placebo
(pre): AUC = 440 6 56; placebo (post): AUC = 531 6 62;
EGCG+RES (pre): AUC = 527 6 59; and EGCG+RES (post):
AUC = 530 6 66 mmol 3 4 h/L; P-time 3 treatment = 0.04,
P-EGCG+RES = 0.92, P-placebo , 0.01] (Figure 1F).
Skeletal muscle and abdominal subcutaneous adipose tissue
substrate metabolism and blood flow were investigated in men
with the use of microdialysis. Adipose tissue and skeletal muscle
ethanol outflow-to-inflow ratios, which indicate local blood flow,
TABLE 3
Body composition before and after 12 wk of supplementation with EGCG+RES or placebo1
Placebo (n = 20) EGCG+RES (n = 18) P
Week 0 Week 12 Week 0 Week 12 Time Treatment Time 3 treatment
Body weight, kg 88.3 6 2.8 88.6 6 2.9 92.4 6 3.6 92.0 6 3.8 0.96 0.46 0.41
Body fat, kg 26.7 6 1.9 26.5 6 1.9 29.4 6 1.4 29.1 6 1.6 0.32 0.36 0.85
Body fat, % 30.1 6 1.9 29.9 6 1.8 31.9 6 1.4 31.5 6 1.4 0.11 0.55 0.84
Lean mass, kg 59.5 6 2.5 59.6 6 2.5 61.2 6 3.0 61.1 6 3.2 0.77 0.67 0.73
Upper body fat, kg 13.1 6 1.0 12.9 6 1.0 14.0 6 0.7 13.8 6 0.7 0.33 0.49 0.93
Lower body fat, kg 9.4 6 0.9 9.4 6 0.9 11.0 6 0.8 10.8 6 0.9 0.24 0.32 0.51
Visceral adipose tissue, kg 0.48 6 0.04 0.50 6 0.05 0.44 6 0.05 0.41 6 0.04 0.88 0.39 0.09
1Values are means6 SEMs. Data were analyzed by using 2-factor repeated-measures ANOVA, with time [P-time (pre, post)] and treatment [P-treatment
(placebo, EGCG+RES)] as factors. P , 0.05 was considered significant. No baseline differences were observed (Student’s t test). In case of a significant time
3 treatment interaction (P-time 3 treatment), post hoc analyses with Bonferroni correction were applied to identify significant within-group effects. No
significant within-group effects were found. EGCG+RES, epigallocatechin-3-gallate plus resveratrol; post, after intervention; pre, before intervention.
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FIGURE 2 Skeletal muscle oxidative capacity and OxPhos protein content before and after the intervention. Values are means6 SEMs; n = 29. Oxidative
capacity (A–E) was assessed by means of ex vivo respirometry on skeletal muscle (Vastus lateralis), isolated after an overnight fast. In aliquots, protein
contents of OxPhos complexes were analyzed by Western blots (F–H). Variables were analyzed by using 2-factor repeated-measures ANOVA, with time [P-
time (pre, post)] and treatment [P-treatment (placebo, EGCG+RES)] as factors. P , 0.05 was considered significant. Significant baseline differences were
identified by Student’s unpaired t test [P (pre)]; and in case of a significant time 3 treatment interaction (P-time 3 treatment), post hoc analyses with
Bonferroni correction were applied to identify significant within-group effects (EGCG+RES, P; placebo, P). A.U., arbitrary units; EGCG+RES, epigalloca-
techin-3-gallate plus resveratrol; FCCP, carbonyl cyanide p-trifluoromethoxyphenylhydrazone; G, glutamate; M, malate; O, octanoyl-carnitine; OxPhos,
oxidative phosphorylation; PLA, placebo; post, after intervention; pre, before intervention; S, succinate.
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were not significantly affected by the intervention (Supple-
mental Figure 1). Interstitial glycerol concentrations, which
reflect local lipolysis, were also not affected by EGCG+RES
(Supplemental Figure 2). Furthermore, no effects of EGCG
+RES supplementation were observed on interstitial glucose,
pyruvate, and lactate concentrations.
EGCG+RES did not affect intramuscular lipid content and
composition
Alterations in fat oxidation may contribute to changes in
intramyocellular lipid metabolites and, consequently, insulin
sensitivity (2). EGCG+RES supplementation for 12 wk did not
alter total lipid content (triacylglycerol and diacylglycerol) or
saturation of the triacylglycerol and diacylglycerol fractions
(Supplemental Table 2).
EGCG+RES did not affect tissue-specific insulin sensitivity
Finally, we investigated whether the improved mitochondrial
capacity and whole-body fat oxidation resulted in improved
insulin sensitivity after EGCG+RES supplementation. We found
no changes in peripheral, hepatic, or adipose tissue insulin
sensitivity after EGCG+RES supplementation compared with
placebo supplementation (Table 4), which is in agreement with
unchanged fasting and postprandial plasma glucose and insulin
concentrations. More specifically, the Rd and EGP under fasting
and insulin-stimulated conditions were not significantly affected
after 12 wk of EGCG+RES supplementation (Table 4). Similar
results were found when values were expressed as changes rela-
tive to fasting conditions (Table 4). Interestingly, EGCG+RES
increased fasting NOGD (P-time 3 treatment = 0.10, P-EGCG
+RES = 0.01, P-placebo = 0.91). Furthermore, EGCG+RES
did not improve insulin-mediated suppression of plasma FFAs,
indicating that adipose tissue insulin sensitivity was also not
affected by EGCG+RES supplementation (P-time3 treatment =
0.63; Table 4).
DISCUSSION
Combining polyphenols with distinct mechanisms of action
may lead to additional or synergistic beneficial metabolic effects
compared with single-polyphenol supplementation (20, 21). Here,
we showed that after 12 wk, combined EGCG+RES supple-
mentation preserved fasting and postprandial fat oxidation com-
pared with placebo. This coincided with increased skeletal muscle
oxidative capacity in the EGCG+RES group. In addition, EGCG
+RES supplementation attenuated the increase in triacylglycerol
concentrations compared with placebo, and the reduction in vis-
ceral adipose tissue mass tended to be higher with EGCG+RES
thanwith placebo. These beneficial metabolic effects, however, did
not translate into improved peripheral, hepatic, and adipose tissue
FIGURE 3 Skeletal muscle gene set enrichment analyses before and
after the intervention. Heat maps of pathways related to metabolic function
from gene set enrichment analyses on skeletal muscle (Vastus lateralis) are
shown (n = 27). Signal log ratios are presented per subject and as means per
group. Genes in the heat maps represent significantly contributing genes to
the most affected pathways by EGCG+RES or placebo supplementation
(false-discovery rate, q-value , 0.2). Colors reflect the signal log ratios
per subject and group (Ø), with red being downregulated and green being
upregulated comparing post- with premeasurement. (A) WP2766: The citric
acid TCA cycle and respiratory electron transport. (B) BIOC_PGC1A path-
way. (C) Fatty acid triacylglycerol and ketone body metabolism. (D)
WP534: Glycolysis and gluconeogenesis. (E) WP1848: Metabolism of car-
bohydrates. (F) WP1935: Transport of glucose and other sugars, bile, salts
and organic acids, metal, ions, and amine compounds. (G) Translocation of
GLUT4 to the plasma membrane. (H) Unfolded protein response. A list of
definitions of gene and protein names used in this figure is included in the
Supplemental Material. EGCG +RES, epigallocatechin-3-gallate plus
resveratrol; PLA, placebo.
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insulin sensitivity in overweight men and women. Because the
resveratrol supplement is composed of P. cuspidatum extract, we
cannot exclude metabolic effects of other components [piceid (=
resveratrol-glucoside) and emodin (28)].
We previously showed that 3 d of EGCG+RES supple-
mentation increased EE (20). The present study showed that
this increase is not maintained after 12 wk of supplementation.
Furthermore, consistent with unchanged food intake, we found
that body weight and body composition were not affected
by longer-term EGCG+RES supplementation. These findings
are in line with most (13, 14, 17, 18, 29, 30) but not all (15)
previous studies in humans. Although no significant effects on
total fat mass were apparent, we found that EGCG+RES tended
to decrease visceral adipose tissue mass by w11% compared
with placebo. Likewise, EGCG and resveratrol reduced vis-
ceral adipose tissue in animals (31, 32). Because visceral
adipose tissue is known to be detrimental to metabolic health
(33), its reduction may be of physiologic importance in the
long term.
Interestingly, we showed that combined EGCG+RES sup-
plementation significantly affected fasting substrate oxidation
compared with placebo (Figure 4). EGCG+RES supplementation
preserved fat oxidation, whereas fat oxidation significantly de-
clined in the placebo group. This effect was maintained during
postprandial conditions. In agreement with our findings, previous
studies in rodents showed that polyphenols may stimulate fat
oxidation under fasting conditions (9, 31, 34). The compensatory
increase in carbohydrate oxidation that we found in the placebo
group was not accompanied by alterations in whole-body glucose
disposal. Rather, we found that EGCG+RES may diminish
glycolysis and increase glycogen storage (35), as indicated by the
increased fasting NOGD (w40%; P-EGCG+RES = 0.01). Im-
portantly, the differentially affected fat oxidation in the present
study is neither driven by an increased lipid supply toward
skeletal muscle nor by a significant reduction in muscle lipid
stores (triacylglycerol and diacylglycerol content). Indeed, it
was previously shown that a shift in fasting fat oxidation can
occur independently of changes in intramuscular lipid content,
EE, adiposity, or insulin sensitivity (36, 37). Alternatively,
a higher oxidative capacity of skeletal muscle mitochondria was
found to be predictive of a lower fasting respiratory exchange
ratio or, in other words, a greater relative reliance on lipids in-
stead of carbohydrate as a fuel source during fasting conditions
(37–39). Interestingly, we found that 12 wk of EGCG+RES
supplementation increased skeletal muscle oxidative capacity in
permeabilized muscle fibers. This was accompanied by an in-
creased muscle protein content of OxPhos complexes and an
upregulation of mitochondrial pathways (citric acid cycle and
respiratory electron transport chain) (Figures 2 and 3). In line
with these findings, we and others previously showed that
resveratrol increased mitochondrial capacity by activating the
AMPK-SIRT-PGC1a pathway (7, 8, 13). It has been suggested
that EGCG increases b-adrenergic stimulation by norepineph-
rine due to catechol-O-methyltransferase inhibition (10, 40). How-
ever, in our previous study we did not observe altered norepinephrine
concentrations after EGCG+RES supplementation (20). Finally,
FIGURE 4 Fasting and postprandial whole-body substrate oxidation and energy expenditure before and after the intervention. Values are means6 SEMs;
n = 31. Indirect calorimetry was performed during fasting conditions and for 4 h after intake of a liquid HFMM. Mean oxygen consumption and carbon
dioxide production over 20 min were used for calculations. Substrate oxidation and energy expenditure were measured after an overnight fast (from 230 to
0 min) and after an HFMM (from 0 to 240 min). Fasting values (A–D), AUCs during the HFMM test (calculated from t = 0 to 240 min; E–H), and incremental
AUCs (I–L) were analyzed by using 2-factor repeated-measures ANOVA, with time [P-time (pre, post)] and treatment [P-treatment (placebo, EGCG+RES)] as
factors. P , 0.05 was considered significant. In case of a significant time 3 treatment interaction (P-time 3 treatment), post hoc analyses with Bonferroni
correction were applied to identify significant within-group effects (EGCG+RES, P; placebo, P). EGCG+RES, epigallocatechin-3-gallate plus resveratrol;
HFMM, high-fat mixed meal; PLA, placebo; post, after intervention; pre, before intervention.
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reduced oxidative stress, indicated by a reduced unfolded protein
response pathway (41), might have contributed to the observed
improvement in skeletal muscle oxidative capacity (42–44) or
vice versa (45).
An increased mitochondrial capacity might reflect an im-
proved metabolic risk profile, because increased mitochondrial
capacity has been associated with higher insulin sensitivity in
several cross-sectional studies in men (37–39, 46). Therefore, we
hypothesized that the improvements in lipid metabolism may
lead to increased insulin sensitivity after 12 wk of EGCG+RES
supplementation. However, we did not find a significant change
in peripheral, hepatic, or adipose tissue insulin sensitivity. To
date, only 3 human clinical trials with resveratrol, but not a single
study with EGCG, examined the effects of polyphenol supple-
mentation on peripheral and hepatic insulin sensitivity by using
the gold-standard hyperinsulinemic-euglycemic clamp. In accor-
dance with our findings, these studies did not show significant
changes in peripheral (17, 18, 29) and hepatic (18) insulin sen-
sitivity in lean (18) and obese (17) patients or in patients with
nonalcoholic fatty liver disease (29) after supplementation with
resveratrol for 4, 8, or 12 wk, respectively. Importantly, in these
studies mitochondrial capacity was not assessed (29) or did not
improve (17, 18) on the basis of gene expression and protein
abundance of related enzymes. Therefore, the present study is the
first, to our knowledge, to show that combined EGCG+RES
supplementation has beneficial effects on skeletal muscle oxida-
tive capacity, although this was not accompanied by increased
peripheral, hepatic, or adipose tissue insulin sensitivity in over-
weight and obese men and women.
In line with these findings, the insulin-mediated stimulation of
carbohydrate oxidation and suppression of lipid oxidation were
not affected by EGCG+RES supplementation after meal in-
gestion or during the hyperinsulinemic-euglycemic clamp. Pre-
viously, we showed that single supplementation of resveratrol for
4 wk and combined EGCG+RES supplementation for 3 d im-
proved metabolic flexibility in humans (13, 20), as shown by
amore pronounced suppression of postprandial fat oxidation. The
apparent discrepancy between the present and earlier studies may
be explained by the duration of supplementation. EGCG+RES
supplementation had no effect on postprandial glucose, insulin,
and FFA concentrations or local interstitial glucose and glycerol
concentrations. This is in agreement with other placebo-
controlled trials in whites (13, 19), whereas sex-specific analyses
may show metabolic effects (14).
Strikingly, we found that EGCG+RES supplementation for
12 wk attenuated the increase in plasma triacylglycerol during the
HFMM test that was seen in the placebo group. Previous studies
in humans (13, 14) and rodents (9, 31, 47) also showed reduced
plasma triacylglycerol after EGCG or resveratrol supplementa-
tion. This might, at least in part, be explained by a reduced
intestinal lipid uptake, an improved buffering capacity of dietary
triacylglycerol in adipose tissue, or increased peripheral (e.g.,
muscle and liver) triacylglycerol extraction. In accordance,
a reduced intestinal lipid uptake after EGCG supplementation
in rodents has been suggested (9), although this could not be
confirmed in humans (30). In addition, EGCG+RES supple-
mentation may have affected hepatic lipid clearance, storage, and
oxidation, as indicated by several animal studies (47–49).
TABLE 4
Whole-body substrate kinetics before and after 12 wk of supplementation with EGCG+RES or placebo1
Placebo (n = 19) EGCG+RES (n = 17) P
Week 0 Week 12 Week 0 Week 12 Time Treatment Time 3 treatment
Rd, mmol/(kg 3 min)
Fasting 10.6 6 0.3 10.7 6 0.3 10.4 6 0.2 10.9 6 0.3 0.25 0.91 0.19
Clamp 31.2 6 2.3 32.5 6 2.3 34.2 6 2.8 35.8 6 3.3 0.25 0.38 0.89
Stimulation (D) 20.6 6 2.2 21.5 6 2.3 24.3 6 3.0 25.0 6 3.2 0.35 0.27 0.84
NOGD, mmol/(kg 3 min)
Fasting 6.1 6 0.7 6.2 6 0.6 5.7 6 0.6 7.9 6 0.7* 0.05 0.41 0.10
Clamp 20.5 6 2.4 23.4 6 1.9 23.0 6 2.5 25.3 6 3.1 0.16 0.73 0.95
Stimulation (D) 14.4 6 2.1 17.2 6 2.1 17.5 6 2.7 17.4 6 2.6 0.54 0.76 0.44
EGP
Fasting, mmol/(kg 3 min) 10.4 6 0.3 10.4 6 0.3 10.1 6 0.2 10.7 6 0.3 0.25 0.91 0.19
Clamp, mmol/(kg 3 min) 4.0 6 0.6 4.2 6 0.6 4.6 6 0.5 4.6 6 0.5 0.78 0.57 0.98
Suppression, % 60.9 6 4.9 58.6 6 4.9 54.1 6 5.1 56.3 6 4.7 0.98 0.57 0.74
Plasma FFAs
Fasting, mmol/L 545 6 40 547 6 44 537 6 42 543 6 47 0.88 0.91 0.94
Clamp, mmol/L 196 6 25 210 6 22 189 6 26 203 6 23 0.17 0.83 0.94
Suppression, % 57.7 6 6.6 57.1 6 5.2 63.4 6 7.0 59.0 6 5.5 0.52 0.62 0.63
Substrate oxidation
RQ, D 0.09 6 0.01 0.08 6 0.02 0.10 6 0.01 0.11 6 0.01 0.96 0.30 0.31
Carbohydrate, D g/min 0.10 6 0.01 0.09 6 0.02 0.11 6 0.01 0.12 6 0.02 0.93 0.27 0.54
Fat, % 55.5 6 7.6 54.3 6 9.1 46.7 6 6.9 48.4 6 8.3 0.95 0.47 0.81
1Values are means6 SEMs. Data were analyzed by using 2-factor repeated-measures ANOVA, with time [P-time (pre, post)] and treatment [P-treatment
(placebo, EGCG+RES)] as factors. P , 0.05 was considered significant. No baseline differences were observed (Student’s t test). *, In case of a significant
time 3 treatment interaction (P-time 3 treatment), post hoc analyses with Bonferroni correction were applied to identify significant within-group effects.
EGCG+RES, epigallocatechin-3-gallate plus resveratrol; EGP, endogenous glucose production; FFA, free fatty acid; NOGD, nonoxidative glucose disposal;
post, after intervention; pre, before intervention; Rd, rate of disappearance; RQ, respiratory quotient; D, absolute difference between fasting and insulin-
stimulated conditions.








aastricht user on 29 Septem
ber 2021
In the present study, we analyzed EGCG, resveratrol, and
dihydro-resveratrol plasma concentrations before and after in-
tervention. In future studies, a more detailed characterization of
polyphenol metabolites might provide additional insight into
polyphenol-induced effects on oxidative metabolism, because
polyphenolic metabolites may exert distinct effects on peripheral
tissues (50, 51). Furthermore, due to the extensive phenotyping
in the current controlled trial, multiple statistical comparisons
were made, which may increase the likelihood of obtaining false-
positive results. Nevertheless, the fact that our major findings on
variables of mitochondrial oxidative capacity and proteins in
oxidative phosphorylation and fat oxidation all point toward the
same direction of an improvement with EGCG+RES compared
with placebo makes it highly unlikely that these are chance
findings. Third, in this randomized trial, the statistical plan in-
cluded a completers analysis taking a drop-out rate of 20% into
account, which was higher than the actual drop-out rate. The
drop-out rate was similar in both groups (10%; n = 2) and was
therefore assumed to be randomly distributed. An intention-
to-treat analysis would therefore make the reported physiologic
effects on oxidative metabolism and fat oxidation only slightly
less pronounced.
In conclusion, the present study showed that 12 wk of EGCG
+RES supplementation improved skeletal muscle oxidative ca-
pacity, preserved fasting and postprandial fat oxidation, and
prevented an increase in triacylglycerol concentrations compared
with placebo. These putative beneficial metabolic effects did not
translate into improved peripheral, hepatic, or adipose tissue
insulin sensitivity after 12 wk. Importantly, the improved mi-
tochondrial capacity and fat oxidation may improve physical
condition (52) and play a role in the prevention of weight gain
(53) and the worsening of insulin resistance (4) in the long term.
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